Press release

Besançon, France – August 2nd, 2023 – MED’INN’PHARMA announced today that it is nominee for the 2023 #PrixGalienUSA in the category Prix Galien Best Startup. It is an honor for MIP to be nominated for this award, recognizing the excellence in research and development of MIP’s innovative drug development platform with the intent to significantly improve the human condition. The awards ceremony will take place on October 26, 2023, in New York City.

About MED’INN’PHARMA – MIP, a French pharma biotechnology company funded in 2017, is a leader in the development of bio-identic drugs with pro-resolutive properties for the treatment of acute and chronic inflammatory situations. MIP’ first-in-class proprietary therapeutic lead candidates have the potential for broad applications in Immunology, infectious diseases, pulmonary, neuroscience, cardiology, metabolic and regenerative medicines. The company develops Resolvix bio-identic drug candidate (license granted by INSERM-EFS-UBFC) with high pro-resolutive properties through a deep reeducation of the whole immune system.